BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？_老虎社区_美港股上老虎

BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？

格隆汇04-02

4月2日，A股市场创新药板块再度爆发，带动医药商业、化学制药、减肥药等相关板块同步上行。截至发稿，康芝药业涨超15%，益佰制药、津药药业、北大医药、重药控股、济民健康等多股涨停，三生国建、诺思兰德、哈一药业等跟涨。港股方面，康诺亚-B、翰森制药、绿叶制药涨超4%，再鼎医药、金斯瑞生物科技等多股上扬。多重利好催化今日创新药板块迎来走强，主要受多重利好因素共振驱动。消息面上，国家药监局公布的数据显示，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2624157850?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216","is_english":false,"pubTime":"2026-04-02 14:03","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2624157850","market":"fut","top_or_hot":-1,"title":"BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？","media":"格隆汇","content":"<div>\n<p>4月2日，A股市场创新药板块再度爆发，带动医药商业、化学制药、减肥药等相关板块同步上行。截至发稿，康芝药业涨超15%，益佰制药、津药药业、北大医药、重药控股、济民健康等多股涨停，三生国建、诺思兰德、哈一药业等跟涨。港股方面，康诺亚-B、翰森制药、绿叶制药涨超4%，再鼎医药、金斯瑞生物科技等多股上扬。多重利好催化今日创新药板块迎来走强，主要受多重利好因素共振驱动。消息面上，国家药监局公布的数据显示，...</p>\n\n<a href=\"https://www.gelonghui.com/p/4283048\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 14:03 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/4283048><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月2日，A股市场创新药板块再度爆发，带动医药商业、化学制药、减肥药等相关板块同步上行。截至发稿，康芝药业涨超15%，益佰制药、津药药业、北大医药、重药控股、济民健康等多股涨停，三生国建、诺思兰德、哈一药业等跟涨。港股方面，康诺亚-B、翰森制药、绿叶制药涨超4%，再鼎医药、金斯瑞生物科技等多股上扬。多重利好催化今日创新药板块迎来走强，主要受多重利好因素共振驱动。消息面上，国家药监局公布的数据显示，...</p>\n\n<a href=\"https://www.gelonghui.com/p/4283048\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_QO","symbol_name":"迷你黄金","start_time":0,"source_url":"https://www.gelonghui.com/p/4283048","article_id":"2624157850","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624157850","pubTimestamp":1775109822,"columns":[{"name":"黄金","id":5,"label_key":null}],"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"进入收获期","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159831":"黄金","159934":"黄金ETF","159992":"创新药","300086":"康芝药业","518880":"黄金ETF华安","600488":"津药药业","600594":"益佰制药","603222":"济民健康","GDXU":"MicroSectors Gold Miners 3x Leveraged ETN","06978":"永泰生物-B","BK4585":"ETF&股票定投概念","IAUI":"NEOS Gold High Income ETF","XME":"金属与采矿指数ETF-SPDR","GLTR":"abrdn Physical Precious Metals Basket Shares ETF","IAUM":"ISHARES GOLD TRUST MICRO","GDXY":"YieldMax Gold Miners Option Income Strategy ETF","IAU":"黄金信托ETF-iShares","PHYS":"Sprott Physical Gold Trust","BTGD":"STKD Bitcoin & Gold ETF","SGOL":"Abrdn Gold ETF Trust","DZZ":"德银黄金两倍做空ETN","DUST":"二倍做空黄金矿业指数ETF-Direxion","BK0188":"融资融券","NUGT":"二倍做多黄金矿业指数ETF-Direxion","GLD":"黄金ETF-SPDR","GLL":"2倍做空黄金ETF-ProShares","JNUG":"金矿指数二倍做多ETF","AAAU":"Goldman Sachs Physical Gold ETF","JDST":"金矿指数二倍做空ETF","02162":"康诺亚-B","000950":"重药控股","DGP":"二倍做多黄金ETN(PowerShares)","02186":"绿叶制药","PALL":"abrdn Physical Palladium Shares ETF","GDX":"黄金矿业ETF-VanEck","BK1191":"制药","CEF":"Sprott Physical Gold & Silver Trust","UGL":"2倍做多黄金ETF-ProShares","GLDM":"SPDR Gold MiniShares Trust","GDXD":"MicroSectors Gold Miners -3x Inverse Leveraged ETN","OUNZ":"VanEck Merk黄金股票基金","000788":"北大医药","USG":"USCF Gold Strategy Plus Income Fund","GDXJ":"小型黄金矿业ETF(Market Vectors)"},"translate_title":"BD + performance double explosion, innovative drugs multi-stock daily limit, the golden window period is coming?","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/e93c8a1406fc77fa377604df15053049","symbols_score_info":{"159831":1.5,"159934":0.6,"159992":1.5,"300086":0.9,"518880":0.6,"600488":0.9,"600594":0.9,"603222":0.9,"CEF":1.5,"USG":1.5,"JNUG":1.5,"IAU":1.5,"SGCmain":0.6,"DZZ":1.5,"GDXJ":1.5,"1OZmain":1.5,"QOmain":1.5,"GLDM":1.5,"IAUM":1.5,"PALL":1.5,"NUGT":0.6,"GLL":1.5,"BTGD":1.5,"GDXU":1.5,"06978":1.5,"SGUmain":0.6,"GDXD":1.5,"DUST":1.5,"IAUI":1.5,"DGP":1.5,"JDST":1.5,"000788":0.9,"AAAU":1.5,"GDX":1.5,"GLD":0.6,"02186":0.9,"XME":1.5,"PHYS":1.5,"GCmain":1.5,"UGL":1.5,"02162":0.9,"MGCmain":1.5,"OUNZ":1.5,"SGOL":1.5,"000950":0.9,"GDXY":1.5,"GLTR":1.5},"content_text":"4月2日，A股市场创新药板块再度爆发，带动医药商业、化学制药、减肥药等相关板块同步上行。截至发稿，康芝药业涨超15%，益佰制药、津药药业、北大医药、重药控股、济民健康等多股涨停，三生国建、诺思兰德、哈一药业等跟涨。港股方面，康诺亚-B、翰森制药、绿叶制药涨超4%，再鼎医药、金斯瑞生物科技等多股上扬。多重利好催化今日创新药板块迎来走强，主要受多重利好因素共振驱动。消息面上，国家药监局公布的数据显示，今年前三个月，我国创新药对外授权交易总额已超过600亿美元，接近2025年全年的一半，表明国产创新药的全球认可度正加速提升。业内普遍认为，BD授权已从过去的偶发性事件逐步演变为常态化趋势，跨国药企对中国创新药研发实力的认可度正系统性提升，为板块提供了坚实的业绩支撑。与此同时，礼来公司当地时间周三宣布，美国食品药品监督管理局（FDA）已批准其GLP-1口服药物上市。这一重磅进展进一步验证了GLP-1赛道的广阔前景，对国内布局相关靶点的创新药企形成正面催化。此外，密集的国际学术会议也在持续释放板块催化剂。第37届国际阿尔茨海默病协会全球大会将于2026年4月14日至16日在法国里昂举办，美国癌症研究协会（AACR）年会也定于4月17日至22日在美国圣地亚哥召开。据披露，今年将有超过100家中国药企亮相AACR，带来近400项研究成果，覆盖核药、DAC、细胞治疗、mRNA等前沿技术及多个热门靶点。这些成果的集中展示，有望进一步提振全球资本对中国创新药研发能力的信心。政策层面同样释放积极信号。2026年《政府工作报告》首次将生物医药定位为“新兴支柱产业”，为产业中长期发展划定了清晰路径。3月24日，国家药监局决定在全国范围内组织实施为期三年的“春雨行动”，推进以临床价值为导向的医疗器械源头创新，促进更多临床创新成果向产品转化。国家药监局数据显示，2025年我国全年批准创新药76个，创历史新高；进入2026年，这一良好势头得以延续——截至3月27日，年内已批准10款创新药上市，其中8款为国产，彰显出我国创新药自主研发能力的历史性突破。创新药企进入收获期在利好消息密集催化之外，业绩端的实质性改善则为板块提供了另一重支撑。历经行业寒冬洗礼，中国头部创新药企正从“投入期”迈入“收获期”。2025年年报显示，多家龙头企业盈利大幅攀升，部分公司首次实现年度盈利，行业基本面拐点已现。从已披露的业绩来看，传统龙头表现强劲。药明康德2025年实现归母净利润191.51亿元，同比增长102.65%；三生制药归母净利润84.82亿元，同比增幅高达305.78%；恒瑞医药实现归母净利润77.11亿元，同比增长21.69%。更值得关注的是，百济神州、信达生物等一批头部创新药公司率先完成从“烧钱”到“造血”的关键跨越，首次实现年度盈利。其中，百济神州全年总收入达53.43亿美元，同比增长40.2%，净利润录得2.87亿美元；信达生物总收入达130.42亿元，同比增长38.4%，净利润达8.14亿元。此外，荣昌生物、诺诚健华等也成功扭亏为盈，分别实现净利润7.1亿元和6.42亿元，营收增速分别达到89.36%和135.27%。多家机构认为，在业绩兑现、估值修复与会议催化三重共振下，创新药板块已迎来黄金窗口期。随着基本面持续向好，板块行情有望延续。招银国际指出，生物医药产业定位跃升为新兴支柱产业，预示全链条政策红利将持续释放，AI制药技术突破与中国创新药出海BD爆发形成双重共振，行业基本面有望加速向好。当前国产创新药出海合作已从单一管线授权升级至平台层面合作，跨国药企对中国医药研发实力的认可度正系统性提升。方正证券也表示，医药生物行业当前处于创新药盈利周期启动阶段，头部企业已实现扭亏，基本面显著改善。与2022年加息周期所处时期不同，创新药如今已进入盈利周期，具备自身造血能力，估值受降息预期变化影响大幅减弱。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}